Hyperbaric Oxygen Therapy in Chemotherapy Adverse Events

Hyperbaric Oxygen Therapy for Reducing Chemotherapy Adverse Events in Cancer Patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251004067499N1

Enrollment

Registered

2025-12-16

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy adverse events. Drugs, medicaments and biological substances causing adverse effects in therapeutic use

Interventions

Intervention 1: Intervention group: Patients suffering from cancer and receiving chemotherapy, while undergoing hyperbaric oxygen intervention. Intervention 2: Control group: Patients suffering from c

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cancer and undergoing chemotherapy Patients suffering from chemotherapy adverse events Consent to participate in the study and obtaining informed consent

Exclusion criteria

Exclusion criteria: Patients with claustrophobia Patients with chronic obstructive pulmonary disease Patients with epilepsy Patients with ear dysfunction Patients with cataracts and a history of eye surgeries Patients with a history of spontaneous pneumothorax Patients with respiratory or sinus infections

Design outcomes

Primary

Measure	Time frame
Diarrhea grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Constipation grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Nausea grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Vomiting grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Myositis grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Arthralgia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Bone pain grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Myalgia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Anorexia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Paresthesia grade based on Common Terminolo	—

Measure

Time frame

Diarrhea grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Constipation grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Nausea grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Vomiting grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Myositis grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Arthralgia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Bone pain grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Myalgia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Anorexia grade based on Common Terminology Criteria for Adverse Events (CTCAE). Timepoint: Up to 10 days after chemotherapy. Method of measurement: Using Common Terminology Criteria for Adverse Events classification.;Paresthesia grade based on Common Terminolo

—

Secondary

Measure	Time frame
Patient Satisfaction Score. Timepoint: Up to 10 days after chemotherapy. Method of measurement: The Chemotherapy Convenience and Satisfaction Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRomina Hamidi Rad

Islamic Azad University

romina.hr@outlook.com+98 937 406 8697

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026